Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today
that it has introduced a highly specific PD-L1 rabbit monoclonal
antibody (mAb). Recent reports have shown PD-L1 to be up-regulated on
the surface of tumor cells, implicating this protein as one of the
factors that allows tumors to evade the immune system. CST's PD-L1
Rabbit mAb is an important addition for researchers studying tumor
immunology and potential approaches to immunotherapy for melanoma, lung,
ovarian, renal, prostate, and other cancers. Clinical researchers are
evaluating antibodies to PD-L1 as potential cancer biotherapeutics
(Brahmer, J.R., et al. (2012) New Engl J Med 366,2455-65).
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PD-L1 (E1L3N) XP® Rabbit mAb. (Photo: Business Wire)
PD-L1 Antibody Applications
PD-L1 interacts with PD-1, a surface receptor on activated T cells
PD-L1 binding leads to inhibition of T cell activity.
Immunohistochemistry (IHC) is an important application for studying the
role of PD-L1 in human and/or mouse xenograft samples, and CST's PD-L1
(E1L3N) XP® Rabbit mAb #13684 has been validated for
recognition of human PD-L1 in IHC as well as for immunofluorescence,
flow cytometry, western blot, and immunoprecipitation*. The high
specificity and sensitivity of this antibody are supported by western
blot detection of a single band at the appropriate molecular weight and
by the IHC detection of endogenous levels of PD-L1 in tumor cells
CST is known for the development of highly specific, thoroughly
validated antibodies to targets relevant to translational research,
including cellular checkpoints and cancer signaling. Past efforts by
CST's Cancer Research Group have focused on unraveling the signaling
networks that underlie various cancers and include the identification of
the EML4-ALK fusion, which has been reported in a subset of patients
with breast, colon and non-small cell lung cancer (NSCLC). The impacts
of EML4-ALK in NSCLC span from research through diagnosis and therapy
(Patents 8,486,645, 8,481,279, 8,377,642, 8,288,102, 8,232,060,
8,168,383, and 7,700,339).
Founded by research scientists in 1999, CST is a private, family-owned
company with over 400 employees worldwide. Active in the field of
applied systems biology research, particularly as it relates to cancer,
CST understands the importance of using antibodies with high levels of
specificity and lot-to-lot consistency. We produce all of our antibodies
in house, and perform painstaking validations for multiple applications.
Technical support is provided by the same CST scientists who produce our
antibodies, helping customers design experiments, troubleshoot, and
achieve reliable results. CST is certified by BSI to be compliant with
ISO 9001:2008 for the design, development, and production of monoclonal
* For Research Use Only. Not For Use in Diagnostic Procedures.
Cell Signaling Technology®, CST™, and XP® are
trademarks of Cell Signaling Technology.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140406005026/en/
[ Back To NFVZone's Homepage ]